Payment overview · 2025
General Payments
$2,415.98
117 reported records · 18 companies
Healthcare provider profile · identity verified
Stan J. Mays, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BATON ROUGE, LA · NPI 1851360622
Verified facts
What the public records show
CMS Open Payments records show Stan J. Mays, M.D. received $2,415.98 in general payments during 2025 across 117 reported records.
Astellas Pharma US Inc accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $538.61 | 22.3% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $312.23 | 12.9% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $274.94 | 11.4% | 17 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $186.75 | 7.7% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $181.03 | 7.5% | 19 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $152.11 | 6.3% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $146.44 | 6.1% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.47 | 3.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.00 | 3.6% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $86.31 | 3.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $76.21 | 3.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $64.25 | 2.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.31 | 2.0% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $44.65 | 1.9% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $44.52 | 1.8% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.44 | 1.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.21 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,111.51 | 113 |
| Education | $304.47 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $276.64 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $257.67 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $244.33 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $186.75 | 9 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $181.03 | 19 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $152.11 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $146.44 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $102.98 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $88.47 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $86.31 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $76.21 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.79 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $69.26 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $66.20 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.31 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.31 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.49 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $44.65 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $44.52 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.78 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 170 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 301 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
81 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
170 | 53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
301 | 93 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
301 | 93 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
44 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
54 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 889 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 747 | 228 |
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 118 |
| Metformin Hcl | Metformin Hcl | 331 | 104 |
| Lisinopril | Lisinopril | 329 | 89 |
| Jardiance | Empagliflozin | 301 | 93 |
| Montelukast Sodium | Montelukast Sodium | 293 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 261 | 65 |
| Prednisone | Prednisone | 239 | 155 |
| Tradjenta | Linagliptin | 238 | 73 |
| Hydralazine Hcl | Hydralazine Hcl | 231 | 74 |
| Meloxicam | Meloxicam | 222 | 89 |
| Potassium Chloride | Potassium Chloride | 220 | 74 |
| Ezetimibe | Ezetimibe | 216 | 79 |
| Furosemide | Furosemide | 209 | 68 |
| Gabapentin | Gabapentin | 182 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 179 | 50 |
| Simvastatin | Simvastatin | 177 | 52 |
| Farxiga | Dapagliflozin Propanediol | 170 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 62 |
| Januvia | Sitagliptin Phosphate | 169 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 37 |
| Metformin Hcl Er | Metformin Hcl | 137 | 44 |
| Alendronate Sodium | Alendronate Sodium | 134 | 33 |
| Trazodone Hcl | Trazodone Hcl | 130 | 29 |
| Omeprazole | Omeprazole | 129 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 39 |
| Carvedilol | Carvedilol | 123 | 39 |
| Famotidine | Famotidine | 122 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 41 |
| Celecoxib | Celecoxib | 103 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 27 |
| Ibandronate Sodium | Ibandronate Sodium | 99 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 26 |
| Vascepa | Icosapent Ethyl | 90 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 27 |
| Mounjaro | Tirzepatide | 89 | 21 |
| Eliquis | Apixaban | 88 | 31 |
| Nifedipine Er | Nifedipine | 88 | 27 |
| Raloxifene Hcl | Raloxifene Hcl | 86 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 84 | 14 |
| Azithromycin | Azithromycin | 82 | 61 |
| Myrbetriq | Mirabegron | 81 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 23 |
| Valsartan | Valsartan | 74 | 23 |
| Ozempic | Semaglutide | 70 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 16 |
| Losartan Potassium | Losartan Potassium | 65 | 24 |
| Clonidine Hcl | Clonidine Hcl | 64 | 22 |
| Linzess | Linaclotide | 60 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 23 |
| Gemtesa | Vibegron | 54 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 20 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Nitroglycerin | Nitroglycerin | 49 | 15 |
| Diclofenac Sodium Er | Diclofenac Sodium | 48 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 11 |
| Baclofen | Baclofen | 46 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 14 |
| Entresto | Sacubitril/Valsartan | 44 | 20 |
| Ibuprofen | Ibuprofen | 43 | 18 |
| Bumetanide | Bumetanide | 42 | 16 |
| Colchicine | Colchicine | 42 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 39 | 12 |
| Telmisartan | Telmisartan | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 19 |
| Felodipine Er | Felodipine | 38 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 15 |
| Megestrol Acetate | Megestrol Acetate | 26 | 14 |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,415.98 · 117 records | Astellas Pharma US Inc | AFREZZA, AREXVY, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Omnipod, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, Veozah, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error